MedImmune, the global biologics arm of AstraZeneca, is restructuring its infectious disease and vaccines research, development and operations, resulting in the closure of its Mountain View, CA and Santa Clara, CA sites, and the consolidation of its infectious disease and vaccines research and development activities to other sites. The changes will be implemented in 2014.

MedImmune’s Hayward, CA site will remain open with additional capabilities invested there. The company estimates that approximately 300 positions will be impacted, with 100 positions moving to other locations, including the Hayward site. In February 2012, the company announced an efficiency program to improve productivity and cut costs.